{"transactions":[{"id":849503,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61586,"kind":"person","name":"House David Duane","position":1,"cik":"0002034219","reported_name":"House David Duane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance, and PFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-03-12T01:17:29.000Z","date":"2026-03-09","kind":"grant","planned":false,"acquired":true,"shares":109885,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the Stock Options shall vest on March 9th of each of 2027, 2028, 2029, and 2030, in each case subject to continuous service through the applicable vesting date."}],"balance_after":109885,"derivative":{"exercise_price":11.61,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":109885},"source":{"system":"sec-edgar","filing":"0001104659-26-026587","document":"tm268588-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926026587/tm268588-8_4seq1.xml","form_type":"4"}},{"id":1279278,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61586,"kind":"person","name":"House David Duane","position":1,"cik":"0002034219","reported_name":"House David Duane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance, and PFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2025-02-07T21:17:04.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the Stock Options shall vest on February 5th of each of 2026, 2027, 2028 and 2029, in each case subject to continuous service through the applicable vesting date."}],"balance_after":25000,"derivative":{"exercise_price":2.04,"expiration_date":"2035-02-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-25-010556","document":"tm255864-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465925010556/tm255864-3_4seq1.xml","form_type":"4"}},{"id":1392740,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":61586,"kind":"person","name":"House David Duane","position":1,"cik":"0002034219","reported_name":"House David Duane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance, and PFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2024-10-03T20:15:12.000Z","date":"2024-10-02","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest and become exercisable 25% on August 16th of each of 2025, 2026, 2027, and 2028, in each case subject to continuous service through the applicable vesting date."}],"balance_after":75000,"derivative":{"exercise_price":2.32,"expiration_date":"2034-10-02","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001104659-24-105848","document":"tm2425499-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000110465924105848/tm2425499-2_4seq1.xml","form_type":"4"}}]}